Mirati Therapeutics Inc. (MRTX) stock remains unchanged after upgrade at Zacks Investment Research

Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) shares traded mostly even in value Wednesday Dec 28 with slower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a upgraded rating.

Meanwhile, U.S. stocks were little changed on Wednesday, as investors found few reasons to keep pushing shares higher towards the 20,000 mark.

The Dow Jones Industrial Average DJIA, -0.11% rose 3.1 points to 19,949, essentially unchanged on the day. The S&P 500 SPX, -0.39% lost 3 points, or 0.1%, to 2,266 while the Nasdaq Composite Index COMP, -0.59% slipped 6.4 points, or 0.1%, to 5,482.

Analysts at Zacks Investment Research upgraded shares of Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) from Hold to Buy today. With a rating of Buy on the stock, the company has a 52-week high of $31.67. The one-year price target of $9.86 is above the opening price of $5.35, that has caused a number of other analysts to issue statements on the stock recently. Stock prices sometimes get a spike to the upside when analysts upgrade a stock.

Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) shares last traded at $5.25. Opening at $5.35, they varied from $5.25 and $5.35 throughout the day.

Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) now has a market cap of 104.60M.

Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) Average Daily Trading Volume

6,629 shares crossed the trading desk yesterday, below the norm, out of a total float 12,040,000. Look for trading volume to pick up in the coming days as momentum traders often use swings in trading volume to pinpoint heavy volume aggregation or circulation by institutional investors.

As with all potential breakouts, investors look for volume to be at least 40%-50% above normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have teams of analysts that investigate thousands of stocks, so it is good validation to see them buying a stock you are considering.

Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

Traders can make more useful decisions on trades when they follow the activity of professional investors.

Trades for Zacks Investment Research (Mirati Therapeutics Inc.: NASDAQ) have ranged from $4.40 – 31.67, and the stock now has a 50-day MA of $5.52 and 200-day MA of $5.49. Today’s last price is 83.42%% below the 52 week high of $31.67.

Earnings growth is a critical factor to consider when buying stocks and investors look for companies that have raised their earnings by at least 25% over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *